Additionally, we are using this system to generate MLL translocations in CD34+ cells freshly isolated from umbilical cord blood followed by transplantation into immunocompromised (NSG) mice in order to develop a novel mouse model of MLL-rearranged leukemia. The gene discussed is KMT2A; the disease is leukemia.